These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35366975)

  • 1. Dermatologic Consequences of Substandard, Spurious, Falsely Labeled, Falsified, and Counterfeit Medications.
    Schwartzman GH; Dekker PK; Silverstein AS; Fontecilla NM; Norton SA
    Dermatol Clin; 2022 Apr; 40(2):227-236. PubMed ID: 35366975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health Implications of Counterfeit Medications.
    Fantasia HC; Vooys KM
    Nurs Womens Health; 2018 Jun; 22(3):264-268. PubMed ID: 29885715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
    Iloh GU; Akodu BA; Emeka EA; Obi IV
    West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard/counterfeit antimicrobial drugs.
    Kelesidis T; Falagas ME
    Clin Microbiol Rev; 2015 Apr; 28(2):443-64. PubMed ID: 25788516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substandard and counterfeit antimicrobials: recent trends and implications to key public health interventions in developing countries.
    Tadeg H; Berhane Y
    East Afr J Public Health; 2012 Jun; 9(2):85-9. PubMed ID: 23139963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Problems associated with substandard and counterfeit drugs in developing countries: a review article on global implications of counterfeit drugs in the era of antiretroviral (ARVs) drugs in a free market economy.
    Nsimba SE
    East Afr J Public Health; 2008 Dec; 5(3):205-10. PubMed ID: 19374325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications.
    El-Dahiyat F; Fahelelbom KMS; Jairoun AA; Al-Hemyari SS
    Front Public Health; 2021; 9():754279. PubMed ID: 34765583
    [No Abstract]   [Full Text] [Related]  

  • 9. Global scenario of counterfeit antimalarials: A potential threat.
    Arora T; Sharma S
    J Vector Borne Dis; 2019; 56(4):288-294. PubMed ID: 33269727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti-malarials.
    Batson JS; Bempong DK; Lukulay PH; Ranieri N; Satzger RD; Verbois L
    Malar J; 2016 Feb; 15():119. PubMed ID: 26917250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viewpoint: Counterfeit medicines and substandard medicines: Different problems requiring different solutions.
    't Hoen E; Pascual F
    J Public Health Policy; 2015 Nov; 36(4):384-9. PubMed ID: 26178809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All the players in the game: driving home the global commitment for legitimate drugs.
    Babyar J
    Drug Dev Ind Pharm; 2018 Nov; 44(11):1868-1870. PubMed ID: 30114946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fraudulent and substandard medicines: getting away with murder?
    Edwards IR
    Drug Saf; 2011 Jun; 34(6):445-8. PubMed ID: 21585218
    [No Abstract]   [Full Text] [Related]  

  • 16. Global perspective of the risks of falsified and counterfeit medicines: A critical review of the literature.
    Feeney AJ; Goad JA; Flaherty GT
    Travel Med Infect Dis; 2024; 61():102758. PubMed ID: 39218049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substandard and Falsified Medications: A Barrier to Global Health Equity Exemplified in Ecuador.
    Yakhkind A; Lang AE; Brophy G; Tesoro E; Levasseur-Franklin KE; Maldonado N
    Neurocrit Care; 2023 Feb; 38(1):1-6. PubMed ID: 36517662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The health consequences of falsified medicines- A study of the published literature.
    Rahman MS; Yoshida N; Tsuboi H; Tomizu N; Endo J; Miyu O; Akimoto Y; Kimura K
    Trop Med Int Health; 2018 Dec; 23(12):1294-1303. PubMed ID: 30291683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research on the Development of Methods for Detection of Substandard and Falsified Medicines by Clarifying Their Pharmaceutical Characteristics Using Modern Technology.
    Yoshida N
    Biol Pharm Bull; 2024; 47(5):878-885. PubMed ID: 38692863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.